<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00322270</url>
  </required_header>
  <id_info>
    <org_study_id>HA008</org_study_id>
    <nct_id>NCT00322270</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters</brief_title>
  <official_title>Phase 3, Multicenter, Multinational, Open-Label Study to Evaluate the Safety and Efficacy of Alfimeprase in Subjects With Occluded Central Venous Access Devices (SONOMA-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCA Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCA Biopharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety profile of alfimeprase as assessed by monitoring of adverse events,
      serious adverse events and major bleeding events for up to 120 minutes following the
      instillation of study drug to an occluded central venous access device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Further study details as provided by Nuvelo
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and efficacy</measure>
    <time_frame>up to120 minutes post study drug dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events, serious adverse events and bleeding events</measure>
    <time_frame>24 hours post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events up to day 30 visit(day 28-45) after instillation of study drug</measure>
    <time_frame>approximately 28-45 days post dosing</time_frame>
  </secondary_outcome>
  <condition>Thrombosis</condition>
  <condition>Venous Thrombosis</condition>
  <condition>Catheter Occlusion</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfimeprase</intervention_name>
    <description>single-dose of alfimeprase, 10 mg.administered intracatheter to an occluded CVAD</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must give written informed consent

          -  Ages 18 or older

          -  Unable to withdraw at least 3 mL of blood from a central venous access device

          -  Hemodynamically stable

          -  Available for follow-up assessments

        Exclusion Criteria:

          -  Inability to infuse at least 2 mL of saline through the catheter

          -  Catheter placed less than 48 hours prior to detection of occlusion

          -  Catheter used for hemodialysis or pheresis

          -  Previous treatment with plasminogen activator for current episode of catheter
             occlusion

          -  Less than 18 years of age

          -  Any evidence of mechanical or nonthrombotic occlusion

          -  In the opinion of the investigator, subject is at &quot;high risk&quot; for bleeding events of
             embolic complications, or has a condition for which bleeding constitutes a significant
             hazard

          -  Increased risk for drug extravasation

          -  Pregnant, lactating, or actively menstruating women and women of child-bearing
             potential who are not using adequate contraceptive precautions (e.g., intrauterine
             device, oral contraceptives, barrier methods, or other contraception deemed adequate
             by the investigator)

          -  Known right-to-left cardiac shunt, patent foramen ovale, or atrial/ventricular septal
             defect

          -  Participation in any other study of an investigational device, medication, biologic,
             or other agent within 30 days before enrollment and until the 30-day follow up visit

          -  Any other subject feature that in the opinion of the investigator should preclude
             study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Begelman, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>ARCA Biopharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Desert Oasis Cancer Center</name>
      <address>
        <city>Casa Grande</city>
        <state>Arizona</state>
        <zip>85222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research &amp; Prevention Center</name>
      <address>
        <city>Soquel</city>
        <state>California</state>
        <zip>95073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Research Center</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasco Hernando Oncology Associates</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasco Hernando Oncology Associate</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical and Surgical Specialists</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center at Blessing Hospital</name>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <zip>62301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalamazoo Hematology and Oncology</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sparrow Cancer Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Care Clinic</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer Care and Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ-Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dakota Cancer Institute</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology/Oncology Consultants, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Gynecology/Oncology</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2006</study_first_submitted>
  <study_first_submitted_qc>May 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2006</study_first_posted>
  <last_update_submitted>August 12, 2008</last_update_submitted>
  <last_update_submitted_qc>August 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Susan Begelman, MD, Director of Medical Sciences</name_title>
    <organization>Nuvelo, Inc.</organization>
  </responsible_party>
  <keyword>Occluded Central Venous Access Devices</keyword>
  <keyword>Occluded Catheters</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>thrombosis, catheter</keyword>
  <keyword>alfimeprase</keyword>
  <keyword>thrombotic occlusion</keyword>
  <keyword>thrombosis, CVAD</keyword>
  <keyword>thrombosis, catheters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

